(Q34135837)

English

Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

31 July 2017

0 references

Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus (English)

1 reference

Europe PubMed Central

31 July 2017

type 2 diabetes

0 references

0 references

1 reference

ChEBI release 2020-05-28

Maximilian von Eynatten

7

object named as

M von Eynatten

1 reference

Europe PubMed Central

31 July 2017

author name string

G Schernthaner

1

1 reference

Europe PubMed Central

31 July 2017

A H Barnett

2

1 reference

Europe PubMed Central

31 July 2017

A Emser

3

1 reference

Europe PubMed Central

31 July 2017

S Patel

4

1 reference

Europe PubMed Central

31 July 2017

J Troost

5

1 reference

Europe PubMed Central

31 July 2017

H-J Woerle

6

1 reference

Europe PubMed Central

31 July 2017

publication date

16 February 2012

1 reference

Europe PubMed Central

31 July 2017

Diabetes, Obesity and Metabolism

1 reference

Europe PubMed Central

31 July 2017

14

1 reference

Europe PubMed Central

31 July 2017

5

1 reference

Europe PubMed Central

31 July 2017

470-478

1 reference

Europe PubMed Central

31 July 2017

(R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared wi

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01565.X

21 January 2018

Concentration-dependent plasma protein binding of the novel dipeptidyl peptidase 4 inhibitor BI 1356 due to saturable binding to its target in plasma of mice, rats and humans

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01565.X

21 January 2018

Safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of BI 1356, an inhibitor of dipeptidyl peptidase 4, in healthy male volunteers

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01565.X

21 January 2018

Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01565.X

21 January 2018

The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01565.X

21 January 2018

Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01565.X

21 January 2018

Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01565.X

21 January 2018

Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01565.X

21 January 2018

Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01565.X

21 January 2018

Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01565.X

21 January 2018

KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01565.X

21 January 2018

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01565.X

21 January 2018

Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01565.X

21 January 2018

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01565.X

21 January 2018

Comparison of extended-release metformin in combination with a sulfonylurea (glyburide) to sulfonylurea monotherapy in adult patients with type 2 diabetes: a multicenter, double-blind, randomized, controlled, phase III study.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01565.X

21 January 2018

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01565.X

21 January 2018

Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01565.X

21 January 2018

Recent insights into the role of dipeptidyl aminopeptidase IV (DPIV) and aminopeptidase N (APN) families in immune functions

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01565.X

21 January 2018

Dual inhibition of dipeptidyl peptidase IV and aminopeptidase N suppresses inflammatory immune responses

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01565.X

21 January 2018

The role of CD26/dipeptidyl peptidase IV in cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01565.X

21 January 2018

Dipeptidyl peptidase-4 (CD26): knowing the function before inhibiting the enzyme

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01565.X

21 January 2018

Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01565.X

21 January 2018

GLP-1-based therapies: the dilemma of uncertainty.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01565.X

21 January 2018

Weighing risks and benefits of liraglutide--the FDA's review of a new antidiabetic therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01565.X

21 January 2018

Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01565.X

21 January 2018

Patients with type 2 diabetes mellitus have higher risk for acute pancreatitis compared with those without diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01565.X

21 January 2018

Acute pancreatitis in association with type 2 diabetes and antidiabetic drugs: a population-based cohort study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01565.X

21 January 2018

Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01565.X

21 January 2018

Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01565.X

21 January 2018

Use of dipeptidyl peptidase-4 inhibitors and the reporting of infections: a disproportionality analysis in the World Health Organization VigiBase

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01565.X

21 January 2018

Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01565.X

21 January 2018

Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01565.X

21 January 2018

Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01565.X

21 January 2018

Adverse effects of dipeptidyl peptidases 8 and 9 inhibition in rodents revisited

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01565.X

21 January 2018

Role of dipeptidyl peptidase IV (DP IV)-like enzymes in T lymphocyte activation: investigations in DP IV/CD26-knockout mice

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01565.X

21 January 2018

Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01565.X

21 January 2018

Identifiers

10.1111/J.1463-1326.2012.01565.X

1 reference

Europe PubMed Central

31 July 2017

1 reference

Europe PubMed Central

31 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34135837&oldid=1540724684"